Matrix metalloproteinase 2 and Matrix metalloproteinase 9 are zinc-dependent enzymes that degrade components of the extracellular matrix, particularly gelatin and type IV collagen. They play critical roles in normal physiological processes such as tissue repair, angiogenesis, bone remodeling, and regulation of inflammation. At the same time, their excessive activity is implicated in diseases such as cancer (where they promote tumor invasion and metastasis), cardiovascular disease, neuroinflammation, and neuropsychiatric disorders. Both are tightly regulated by inhibitors (TIMPs), proenzyme activation mechanisms, and transcriptional control. Because of their substantial role in pathological extracellular matrix remodeling, they are considered significant therapeutic targets. However, their biological versatility means that inhibition strategies pose notable safety and selectivity challenges
Other names
MMP-2: 72 kDa type IV collagenase, gelatinase AMMP-9: 92 kDa type IV collagenase, gelatinase BMatrix metallopeptidase 2Matrix metallopeptidase 9
02
Mechanism of action
Inhibition of zinc-dependent catalytic activity by chelation or direct binding
Allosteric inhibition at substrate recognition sites
Blockade of proenzyme activation
Upregulation or downregulation via modulation of expression (e.g., with small molecule or gene therapy)
03
Biological functions
Extracellular matrix degradationRegulation of angiogenesis (blood vessel formation)Tissue remodeling and repair (wound healing, bone remodeling)Cell migration and invasionBreakdown of basement membranesRegulation of inflammationApoptosis (cell death)Synaptic plasticity (particularly MMP-9 in the CNS)
04
Disease associations
Cancer (tumor invasion, metastasis)Cardiovascular disease (hypertension, arterial remodeling)Neurodegenerative disease and neuropsychiatric disorders (MMP-9 especially)Diabetes (vascular complications)Inflammation (arthritis, tissue injury, etc.)Infection (remodeling in response to pathogens)Other: Bone remodeling disorders, reproductive disorders
05
Safety considerations
Lack of selectivity: Broad inhibition of MMPs can cause musculoskeletal toxicity and interfere with normal tissue remodeling and repairCardiovascular complications with chronic inhibitionWound healing defectsPotential impact on synaptic plasticity and cognition (especially for MMP-9)
06
Interacting drugs
Metallofullerenol Gd@C82(OH)22 (inhibits MMP-2 and MMP-9)
2 more in the full profile.
07
Biomarkers
Elevated plasma or tissue levels of MMP-2 and MMP-9 (used for cancer invasion/metastasis prognosis, cardiovascular events, hypertension, etc.)MMP-9 levels as a potential biomarker in neuropsychiatric disordersAssociated changes in TIMP (tissue inhibitor of metalloproteinase) levels
Beyond the preview
Go deeper on Matrix metalloproteinase 2 and Matrix metalloproteinase 9 (MMP-2 (for Matrix metalloproteinase 2); MMP-9 (for Matrix metalloproteinase 9)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matrix metalloproteinase 2 and Matrix metalloproteinase 9 (MMP-2 (for Matrix metalloproteinase 2); MMP-9 (for Matrix metalloproteinase 9)).